Synaptogenix Inc (SNPX)

[runncoach]

Likely will be but even still patience will certainly be required. I will be very interested in seeing the detailed data from this last trial. To me it looks like roughly 80% of the patients in the moderately severe subgroup improved test scores. At some point perhaps a sliver of the market will begin to understand that the drug has improved test scores in every trial undertaken. Of course it seems that it will take a longer length trial such as the one about to enroll to convince more people and I believe that's understandable. Hopefully we'll present the data at CTAD this year.